Leerink Partners analyst David Risinger maintained a Buy rating on Sanofi yesterday. The company's shares closed last Thursday at $100.19.
Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Sanofi, and Amgen. According to TipRanks, Risinger has an average return of 15.2% and a 58.47% success rate on recommended stocks.
Currently, the analyst consensus on Sanofi is a Strong Buy with an average price target of $123.24, representing a 23.01% upside. In a report released on October 15, J.P. Morgan also maintained a Buy rating on the stock with a €105.00 price target.
Based on Sanofi's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $10.74 billion and a net profit of $3.94 billion. In comparison, last year the company earned a revenue of $11.38 billion and had a net profit of $1.11 billion